Thomas C VanCott
Overview
Explore the profile of Thomas C VanCott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OConnell R, Excler J, Polonis V, Ratto-Kim S, Cox J, Jagodzinski L, et al.
J Infect Dis
. 2016 Feb;
213(12):1946-54.
PMID: 26908741
Background: Prime-boost regimens comprising ALVAC-HIV (prime) and human immunodeficiency virus type 1 (HIV) Env (boost) induce HIV-specific neutralizing antibody and cell-mediated immune responses, but the impact of boost schedule and...
2.
Cox J, Ferrari M, Earl P, Lane J, Jagodzinski L, Polonis V, et al.
Vaccine
. 2012 Jan;
30(10):1830-40.
PMID: 22234262
The current study assessed the immunogenicity and protective efficacy of various prime-boost vaccine regimens in rhesus macaques using combinations of recombinant DNA (rDNA), recombinant MVA (rMVA), and subunit gp140 protein....
3.
Brown B, Cox J, Gillis A, VanCott T, Marovich M, Milazzo M, et al.
PLoS One
. 2010 Nov;
5(11):e13849.
PMID: 21079762
Background: The fatal disease caused by Bacillus anthracis is preventable with a prophylactic vaccine. The currently available anthrax vaccine requires a lengthy immunization schedule, and simpler and more immunogenic options...
4.
Pashov A, Canziani G, Monzavi-Karbassi B, Kaveri S, MacLeod S, Saha R, et al.
J Biol Chem
. 2005 Jun;
280(32):28959-65.
PMID: 15955803
The glycan shield of the human immunodeficiency virus (HIV) envelope protein presents many potential epitopes for vaccine development. To augment immune responses to HIV, type 1 (HIV-1), envelope-associated carbohydrate antigens,...
5.
Pashov A, MacLeod S, Saha R, Perry M, VanCott T, Kieber-Emmons T
Glycobiology
. 2005 May;
15(10):994-1001.
PMID: 15917430
Many mannose-binding proteins inhibit divergent strains of human immunodeficiency virus type 1 (HIV-1) in in vitro models of viral infectivity, suggesting that targeting mannose residues in vaccine applications might offset...
6.
Quinnan Jr G, Yu X, Lewis M, Zhang P, Sutter G, Silvera P, et al.
J Virol
. 2005 Feb;
79(6):3358-69.
PMID: 15731230
We studied the capacity of active immunization of rhesus monkeys with HIV-1 envelope protein (Env) to induce primary virus cross-reactive neutralizing antibodies to prevent infection following intravenous challenge with simian-human...
7.
Mascola J, Sambor A, Beaudry K, Santra S, Welcher B, Louder M, et al.
J Virol
. 2004 Dec;
79(2):771-9.
PMID: 15613305
Immunization with recombinant serotype 5 adenoviral (rAd5) vectors or a combination of DNA plasmid priming and rAd5 boosting is known to elicit potent immune responses. However, little data exist regarding...
8.
Richards R, Rao M, VanCott T, Matyas G, Birx D, Alving C
Immunol Cell Biol
. 2004 Oct;
82(5):531-8.
PMID: 15479439
Protective or therapeutic immunity against HIV infection is currently believed to require both antibody and CTL responses against the envelope protein. In the present study, the adjuvant activity of a...
9.
Rao M, Matyas G, VanCott T, Birx D, Alving C
Immunol Cell Biol
. 2004 Oct;
82(5):523-30.
PMID: 15479438
In the present study we investigated the immunomodulatory effects of two adjuvants, liposomal lipid A [L(LA)] and CpG-containing oligodeoxynucleotides (CpG ODN), to the HIV-1 ogp140 envelope protein. Administration of each...
10.
Mascola J, Lewis M, VanCott T, Stiegler G, Katinger H, Seaman M, et al.
J Virol
. 2003 Sep;
77(19):10348-56.
PMID: 12970419
High levels of infused anti-human immunodeficiency virus type 1 (HIV-1) neutralizing monoclonal antibodies (MAbs) can completely protect macaque monkeys against mucosal chimeric simian-human immunodeficiency virus (SHIV) infection. Antibody levels below...